Is 2025 the Chinese Year of BioPharma?
Bio Pharma Dive
FEBRUARY 3, 2025
China is now a dealmaking hot spot for firms seeking next-generation innovation. What will 2025 hold?
Sat.Feb 01, 2025 - Fri.Feb 07, 2025
258 
An unexpected mechanism regulates the immune response during parasitic infections
Medical Xpress
FEBRUARY 7, 2025
Researchers at the University of Lige (Belgium) have uncovered a previously unknown mechanism that regulates the immune response against parasites. During a parasitic infection, specific immune cells, known as virtual memory T cells, become activated and express a surface molecule called CD22, which prevents an excessive immune reaction. This discovery could help in better-controlling inflammation and improving immune responses to infections.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn
Pharmaceutical Technology
FEBRUARY 7, 2025
Bain Capital said its decision to buy Mitsubishi Tanabe is due to the strong growth potential of Japans healthcare industry.
February 4, 2025: Workshop Summary Now Available for ‘Going From Zero to 100: Generating Evidence Through Pragmatic Research to Address Pressing Healthcare Issues’
Rethinking Clinical Trials
FEBRUARY 4, 2025
A workshop summary, videocast recordings, and other materials are now available from the NIH Pragmatic Trials Collaboratory’s 2024 virtual workshop, “Going From Zero to 100: Generating Evidence Through Pragmatic Research to Address Pressing Healthcare Issues. “ The 2-day workshop, hosted by the NIH, featured a keynote address by Monica Bertagnolli exploring how to identify high-priority healthcare issues that require the effort, time, and funding of a clinical trial.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Shares of psychedelics biotech nearly double on depression data
Bio Pharma Dive
FEBRUARY 3, 2025
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was fast and effective in a treatment-resistant depression trial.
Dangerous Kind of Fat Hidden in The Body Can Raise Your Risk of Death
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 4, 2025
(Peathegee Inc/Getty Images) Humans with relatively more fat hidden in and around their muscles face a higher risk of death or hospitalization from heart disease, according to new research an association that persists regardless of body mass index (BMI).
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Grand Rounds January 31, 2025: Advancing Rural Back Pain Outcomes Using Rehabilitation Telehealth (ARBOR-Telehealth): Early Progress and Lessons Learned (Richard L. Skolasky, ScD; Kevin H. McLaughlin, DPT)
Rethinking Clinical Trials
FEBRUARY 6, 2025
Speakers Richard L. Skolasky, ScD Professor, Johns Hopkins School of Medicine Department of Orthopaedic Surgery Kevin H. McLaughlin, DPT Assistant Professor, Johns Hopkins School of Medicine Department of Physical Medicine and Rehabilitation Slides Keywords Back Pain; Rural Health; Telehealth Key Points Low back pain (LBP) is the most common cause of disability globally and in the U.S.
Vertex challenger Sionna prices $191M IPO
Bio Pharma Dive
FEBRUARY 6, 2025
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or be used in new, multi-drug combinations.
The Growing Importance of Specialty Generics in the Latin American Pharmaceutical Market
Drug Patent Watch
FEBRUARY 5, 2025
The Latin American Pharmaceutical Market: Why Specialty Generics Are Poised for Growth As the pharmaceutical industry continues to evolve, one trend is becoming increasingly clear: the demand for specialty generics is on the rise, particularly in the Latin American market. But what exactly are specialty generics, and why are they gaining traction in this region?
Thermo Fisher continues viral vector withdrawal; lays off 300 employees
Pharmaceutical Technology
FEBRUARY 4, 2025
The cuts at two Massachusetts plants follow further site closures and layoffs across the company over the past few years.
A Type of Fiber Could Have Weight Loss Benefits Similar to Ozempic
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 5, 2025
(courtneyk/Getty Images) Research on the gut microbiome has triggered a ‘revolution‘ in nutritional science, and in the last few years, dietary fiber has become the “new protein” added to foods in abundance to feed our gut and boost our health. A recent study on mice, however, suggests not all fiber supplements are equally beneficial.
Pfizer drug acquired in $11B buyout confirms benefit in colon cancer
Bio Pharma Dive
FEBRUARY 3, 2025
The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval — boosting an oncology portfolio Pfizer is looking to for revenue growth.
Study finds stem-like T cells key to lasting immune response in cancer, chronic diseases
Medical Xpress
FEBRUARY 1, 2025
Prolonged illnesses like cancer and chronic infections often leave the immune system in a state of exhaustion, where its frontline defendersT cellslose their ability to function effectively. Research, led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute) and the Peter MacCallum Cancer Center (Peter Mac), have identified a rare type of immune cells, called stem-like T cells, that holds the key to maintaining powerful, long-term immune responses.
Sanofi increases ownership stake partaking in pharma buyback trend
Pharmaceutical Technology
FEBRUARY 7, 2025
Sanofi has agreed to purchase its own shares worth 2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Revealed: How Much Exercise You Need to ‘Offset’ a Day of Sitting
AuroBlog - Aurous Healthcare Clinical Trials blog
FEBRUARY 6, 2025
(Jack Atkinson/Unsplash) We know that spending lots of time sitting down isn’t good for us, but just how much exercise is needed to counteract the negative health effects of sitting down all day? Research suggests about 30-40 minutes per day of building up a sweat should do it.
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Bio Pharma Dive
FEBRUARY 6, 2025
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and is around 1,000 prescriptions weekly by late January.
Optimizing Research Productivity Using Data-Driven Protocol Feasibility
ACRP blog
FEBRUARY 5, 2025
As many as 20% to 50% of clinical trials do not accrue participants at the site level, leading to wasted time and financial resources. This waste can be minimized by early selection of trials most likely to succeed. The protocol feasibility review process informs this selection by offering a way to evaluate logistical elements of a clinical trial before the activation process is started.
MHRA seeks input on new regulatory guidance for cancer vaccines
Pharmaceutical Technology
FEBRUARY 3, 2025
The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Obesity-Focused Metsera Launches IPO Amid Much Anticipation
XTalks
FEBRUARY 5, 2025
Metsera, Inc., a clinical-stage biotech company focused on developing next-gen injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for the treatment of obesity, overweight and related conditions, has priced its initial public offering (IPO) at $18.00 per share, raising $275 million in gross proceeds. Current Share Price: The offering, which includes 15,277,778 shares of common stock, is set to close on February 3, 2025, after beginning trading on the Nasdaq under the ticker sy
Drugmakers prep for bird flu outbreak, despite continued low risk
Bio Pharma Dive
FEBRUARY 3, 2025
While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.
Reducing Study Start-Up Times: Quality Improvement Practices at a Site Management Organization
ACRP blog
FEBRUARY 4, 2025
Taking an average of around eight months, study start-up can be subject to a wide variety of delays that impact study costs and timelines. In effort to reduce this average, HCA Healthcare Research Institute, a site management organization with around 40 sites and 275 open trials, has a centralized approach to reducing start-up timelines. We pride ourselves on being a watchdog, for example, by making sure that operational elements of the protocol do not over-burden study participants and lead to
Treating alcohol addiction: filling the medication gap
Pharmaceutical Technology
FEBRUARY 7, 2025
With Dry January firmly behind us, many adults are prompted to reassess their relationship with alcohol. Alcohol Change, the UK charity behind the popular Dry January initiative, found that 30% of men and 26% of women in the UK wished to reduce the amount of alcohol they drank in 2024.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Nobi Raises $37M in Series B Funding for AI-Driven Fall Detection Technology
XTalks
FEBRUARY 4, 2025
Belgian AgeTech innovator Nobi has successfully secured 35 million ($37 million) in an oversubscribed Series B funding round to advance its AI-powered smart light designed for fall detection and prevention among the elderly. The financing round was co-led by Angelini Ventures and Nexus NeuroTech Ventures, with participation from Japanese investor 15th Rock and existing investors, including EQT Health Economics, EQT Dementia Fund, Belgian investment company PMV and Nobis co-founders Roeland Pelgr
Tariffs raise concern among generic drugmakers, as advocacy groups seek exemptions
Bio Pharma Dive
FEBRUARY 7, 2025
“There is not a single member of AAM who has not raised concerns about the tariff situation,” said the CEO of the generic drug lobby Association for Accessible Medicines.
Scientists discover mitochondria's role in shaping memory circuits
Medical Xpress
FEBRUARY 7, 2025
Virginia Tech neuroscientists have uncovered a mitochondrial process that supports the brain cells critical for learning, memory, and social recognition.
Radiopharmaceutical deals drive sector growth despite supply crisis
Pharmaceutical Technology
FEBRUARY 4, 2025
Developers celebrate gains for advances with radiopharmaceuticals while regulators and isotope suppliers work to keep up.
Maze Therapeutics Introduces IPO with Two CKD Candidates in Clinical Trials
XTalks
FEBRUARY 4, 2025
Maze Therapeutics, a clinical-stage biopharmaceutical company, has raised $140 million in its upsized initial public offering (IPO), pricing shares at $16 each. The company plans to use these funds to advance its groundbreaking research in small molecule precision medicines, targeting renal, cardiovascular and metabolic diseases, including obesity. Current Share Price: The announcement follows a $115 million Series D financing in December 2024, co-led by Frazier Life Sciences and Deep Track Capi
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb
Bio Pharma Dive
FEBRUARY 5, 2025
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.
Experts Share Ways to Streamline Informed Consent Process in Clinical Trial Startup
Advarra
FEBRUARY 4, 2025
At a busy research site, a clinical trial is ready to launch but its stuck in limbo over a single paragraph in the informed consent form (ICF). The issue? Language relating to the potential cost of participation. One sites language on what they will pay for differs from anothers, and the contradictory wording needs to be reviewed and agreed to by the sponsor before the IRB can proceed.
Relmada acquires Tourette’s therapy rights from Asarina
Pharmaceutical Technology
FEBRUARY 7, 2025
Relmada has acquired complete ownership rights to Sepranolone, developed for Tourette syndrome (TS) from Asarina Pharma.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Let's personalize your content